Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
An EEG calibration toolkit for monitoring rehabilitation of stroke patients. (MRI4DEEG)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Netherlands,Netherlands
Call: ERC-Proof of Concept (ERC-2017-PoC, 2017)
Start date: 2018-01-01
End date: 2019-06-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 12500.0
Participants: 2
Project status: CLOSED

An EEG calibration toolkit for monitoring rehabilitation of stroke patients EEG records electric potential differences from electrodes attached to the human skin. Since it is a brain imaging technique that provides a direct measure of neural activity, it is an ideal device to monitor stroke rehabilitation. For instance, the amplitude of an EEG response to a fixed external stimulus on the wrist could act as a biomarker quantifying the number of active cells in the primary somatosensory cortex. In this way, an EEG system could work as a simple monitoring device rendering direct feedback to healthcare workers on the success of the applied therapeutic strategy. This would greatly help to select the most optimal therapy for the individual patient. However, with the current state of the art a direct comparison between EEG amplitudes of different subjects is not possible because these amplitudes are strongly affected by inter individual skull variations. In this PoC project a calibration step is proposed to reduce these influences on the EEG biomarker. We will develop a software toolkit, allowing to execute the required calibration step with a minimum of patient burden. We foresee that the prototype delivered by the end of the project can be developed into a commercial accessory EEG software device that can be provided to end users for relatively small add-on price. Best practices of EEG calibration will be disseminated by publications, presentations at conferences, a special workshop and business development activities.

Keywords: head models,conductivity,stroke
Library of inedited bio-based multicomponent resins for the 3D-printing of self-healing, recyclable thermosets. (SUSTAINABLE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Sweden
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-09-20
End date: 2023-09-19
Duration (months): 24.0
Total project cost (EUR): 203852.16
EU funding (EUR): 203852.16
Participants: 1
Project status: SIGNED

With the increasing concerns on the environmental issues and with the depletion of fossil-based resources, sustainable chemistries for the development of resins from bio-based molecules and for the reprocessing and recycling of plastics are strongly demanded. In this context, SUSTAINABLE is aimed at developing inedited photopolymerizable bio-based resins employable for the 3D-printing of green, self-healing and recyclable thermosets. While photopolymerization 3D-printing has been widely employed for the obtainment and chemical optimization of thermosets from fossil-based resources, few scientific works have dealt with the design of bio-based photopolymerizable resins for 3D-printing. To complete the curing of the thermosets, the project will investigate an innovative cold atmospheric pressure plasma (CAP) assisted approach, as a more flexible alternative to the conventional UV exposure. SUSTAINABLE, proposing possible strategies to reduce the environmental issues linked to the single-use plastic devices disposal, contributes to the achievement of Goal 12: “Ensure sustainable consumption and production pattern” of United Nations’ Sustainable Development Goals. The programme will be developed by a researcher with a PhD in Engineering and skills on design, realization and optimization of CAP sources for materials processing; the fellowship will be performed at KTH in Stockholm, under the supervision of Prof. M. Hakkarainen, who has acknowledged expertise in the synthesis, processing and end-of-life management of bio-based, degradable and/or recyclable plastics. SUSTAINABLE requires expertise from organic chemistry, materials manufacturing and processing, materials characterization and will thereby diversify the competences of both the researcher and the Host Group. This action prepares the fellow for the achievement of a more permanent position by endowing her with crucial opportunities to gain new scientific competences and improving her transversal skills.

Keywords: self healing and recyclable thermosets,3d printing,plasma technology,bio based resins,functionalized resins
energy-autonomous Portable Access points for INfrastructure-LESS networks (PAINLESS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Ireland,Israel,Cyprus,Greece,France,France,Denmark,United Kingdom,Lebanon,United Kingdom,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2018, 2018)
Start date: 2018-10-01
End date: 2022-09-30
Duration (months): 48.0
Total project cost (EUR): 4162393.24
EU funding (EUR): 4162393.24
Participants: 16
Project status: CLOSED

The explosive growth of applications and industrial sectors that rely on broadband connectivity, is set to stretch the demand for wireless networks beyond the reach of the power grid infrastructure. Access points are being deployed on board of drones, while more than 84,000 hybrid-energy base stations are expected to be deployed annually in remote areas by 2020. Portable network nodes that are energy-autonomous and operate detached from the power grid will become indispensable in the coming applications of wireless networks. Energy-autonomy presents immense challenges for the wireless network design and imposes a complete re-think of technological solutions. PAINLESS has the visionary aim to establish a training and research platform to pioneer green, energy-autonomous portable network nodes which are self-subsistent and limitlessly-scalable, to satisfy future demands with minimal infrastructure. It promises a paradigm shift by integrating and jointly optimising wireless networks with renewable energy sources, radiated energy harvesting and airborne access points, as well as establishing disruptive performance benchmarks for the combined wireless power-and-information distribution. Our results will kick-start an innovation ecosystem for infrastructure and service providers of ICT to develop and commercialise a new generation of autonomous, sustainable and power-independent communication networks with self-organising functionality, to enable 100% coverage in urban environments in a power-efficient manner; provide network access to all types of emergency, disaster and special events areas; and connect remote / developing areas with problematic infrastructure. PAINLESS relates to H2020-MSCA with a vision to produce the first generation of experts in a radically new wave of energy autonomous networks that will revolutionise the wireless networking technology landscape and the plethora of associated vertical business sectors.

Keywords: energy efficiency,energy harvesting,unmanned areial vehicles uavs,remote networks
Cognitive neurorehabilitation with virtual reality (CognitiVRehab)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Germany
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2019-12-31
Duration (months): 5.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The real motivation behind Living Brain GmbH was born out of a personal story. Julian Specht (co-founder of Living Brain) suffered from temporal lobe epilepsy until 2015. Fortunately, he has undergone neurosurgery and today lives without any kind of cognitive impairment. However, this is the exception rather than the rule! More than 30 million people suffer from long lasting mild cognitive impairment due to neurological disorders that current cognitive trainings cannot solve. Paper-and-pencil exercises are standard of care, but barely relate to activities of daily life, not reproducing the richness of multi-stimuli of real-world settings. Even novel virtual-based therapies fail to deliver an optimal cognitive training, most of them don’t allow the patient to train in the comfort of his home. Barbara Stegmann and Julian Specht, founded Living Brain to tackle all those limitations. Living Brain developed a virtual-reality (VR) based cognitive training software. Its novelty stands in the fact that the VR software is scientifically based on the principles of neuroplasticity, providing immersive 3D scenarios that optimally reproduce activities of daily life speeding up cognitive recovery and trainings are not bound to a location (clinics/hospitals). Moreover, collection of data with the monitoring software enables Living Brain to build a feedback loop between the therapist and the patient and promote the highest levels of patient engagement to the trainings. Living Brain has been awarded an Exist start-up grant (€127,5K) and participated in Merck accelerator program (€50k). Living Brain revenue streams will mainly come from: B2B direct sales of VR software to clinics and a B2C channel directed to the self-paying patient. Under this feasibility study we will design the technical, clinical and commercial roadmap to validate our TRL6 product.

Keywords: neurological disorders,cognitive neurorehabilitation,virtual reality,cognitive assessment or training,gamification
Chiral Plasmons in Protein-Nanoparticle Hybrid Materials for Application as Biosensors (CINMAB)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Spain
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-10-20
End date: 2018-10-19
Duration (months): 24.0
Total project cost (EUR): 170121.6
EU funding (EUR): 170121.6
Participants: 1
Project status: CLOSED

The real challenge in the field of nanomaterials is to fabricate hybrid systems that can function as smart materials in a wide variety of applications. Hybrid systems possessing protein templates can be potential candidates in this direction due to the wide variety of applications possible in biological systems. The project outlined below aims at the synthesis of novel hybrid conjugates based on protein templates and gold/silver nanoparticles (NPs)/nanorods (NRs) as plasmonic materials to generate chiral plasmons. Different proteins will be utilized for the fabrication of two different chiral templates: (i) helical one dimensional aggregates and (ii) chiral crystals. The plasmonic metal NPs/NRs can be introduced on these templates utilizing electrostatic and covalent interactions resulting in chiral plasmons. The mechanism of chirality transfer from the template to NPs/NRs can be studied by the detailed crystallographic investigations of the template, nanoparticle and their heterojunctions. The extent of chirality transfer would depend largely on the nature of the template and hence the project aims at fabricating hybrid systems wherein the transfer of chirality from the template to the plasmonic material is efficient. The hybrid systems can be used for enhancing the spectroscopic signals of molecules in Surface Enhanced Raman Scattering (SERS). Our ultimate goal is to utilize the hybrid chiral systems as biosensors (i) for the detection of assembly and disassembly of proteins as well as (ii) for understanding crystallographic changes in medication. The importance of the first part is emphasized by the fact that the assembly of proteins is the cause for various neurodegenerative diseases and its disassembly can be an effective mode of therapy. On the other hand, the insulin is delivered to diabetic patients in the form of crystals and the slow crystal dissolution is the mode of supplying insulin into the blood stream. The importance of the two biological phenomena m

Keywords: chiral plasmons,metal nanoparticles,protein aggregation,protein crystals,biodetection,hybrid materials
Anchoring ligandable binding sites at E3 ligase surfaces for plug-and-play PROTACs. (ANCHOR E3s)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-08-01
End date: 2018-07-31
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

The Anchor E3s project proposes to establish, for the first time, an efficient protocol for the discovery and characterisation of accessible binding sites at any patch of a protein surface, regardless of its involvement in biological function. One of the motivation of the research is to develop a general approach to discover new “anchor” ligands that can enable improved plug-and-play proteolysis targeting chimeras (PROTACs) as chemical degraders of any protein of interest. The project will build on results from the host lab who identified a series of low molecular-weight fragments addressing novel patches at the surface of Cullin RING E3 ubiquitin ligases (CRLs) with currently unknown functionality, demonstrating that accessible and “ligandable” binding sites can be found on CRL surfaces. A combination of structure-based computational techniques informed by biophysical experiments and X-ray crystallography will be used to reveal, characterise, and target new ligandable binding sites at CRL surfaces. Promising anchor fragments will then be identified and grown into suitable binders, and eventually linked to assemble novel PROTACs, which will be assessed in cellular assays. The ultimate goal of the research is to develop and establish the PROTAC approach as an efficient and universal chemical biology platform for target validation, regardless of the perceived “druggability” of the targeted protein.

Keywords: protacs,protein degradation,fragment based drug design,cullin ring e3 ligases,anchor ligands,ubiquitin proteasome system,druggability
A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology (PREDICT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Italy,Germany,Italy,Belgium,Belgium,France,Netherlands,Netherlands,Netherlands,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2017, 2017)
Start date: 2017-10-01
End date: 2022-03-31
Duration (months): 54.0
Total project cost (EUR): 3588939.37
EU funding (EUR): 3588939.37
Participants: 18
Project status: CLOSED

The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of personalised medicine for cancer treatment. Thus, there is an imperative need for new technologies that can accurately detect tumour heterogeneity, allow for patient stratification and assist clinicians in providing the right diagnosis and treatment for the right patient. PREDICT’s mission is to address this huge unmet need. Radiomics, a newly emerging field that uses high-throughput extraction of large amounts of features from radiographic images, can boost the field of personalised medicine. The analysis of medical images taken as standard-of-care allows Radiomics to capture tumour heterogeneity and to generate ‘tumour-specific’ signatures in a non-invasive way, without the need of assessing the patient’s genetic profile. Thus, Radiomics, if linked to Big- data and decision support systems (DSS), can be used as diagnostic tool for patient stratification, for prediction of treatment response and for guidance, involving the patient, of clinical decisions in oncology. However, researchers that understand cancer biology, advanced imaging and big data analytics are virtually absent. Even more challenging is to translate the outcomes into actual clinical tools involving the patient. PREDICT will train 15 highly promising researchers in the emerging field of Radiomics and Big data. These ESRs will be trained to implement the automatic exploitation of large amounts of imaging data to drive decision-making algorithms that will guide diagnosis and treatment of different types of cancer and to develop ‘tumour-specific’ signatures integrated in multifactorial DSS. The ESRs will become experts and innovators in Radiomics, Big Data and DSS, which will allow them to bring unique solutions towards the clinic. PREDICT builds upon a strong consortium with 8 academic and 10 non-academic partners that are all pioneers in their respective field.

Keywords: oncology,cancer treatment,radiomics,personalised medicine,big data,decision support system,participative medicine,theragnostics
Personalized Recommendations for Neurodegenerative Disease (VirtualBrainCloud)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Austria,Spain,Italy,Germany,Germany,Spain,Germany,Germany,Finland,Romania,France,France,France,Netherlands,United Kingdom,Luxembourg
Call: Exploiting the full potential of in-silico medicine research for personalised diagnostics and therapies in cloud-based environments (H2020-SC1-DTH-2018-1, 2018)
Start date: 2018-12-01
End date: 2023-05-31
Duration (months): 54.0
Total project cost (EUR): 15016343.1
EU funding (EUR): 15016343.09
Participants: 20
Project status: SIGNED

The annual worldwide cost of Alzheimer’s dementia was 777.81 billion Euro in 2015. This number will rise to 7.41 trillion Euro in 2050. Early diagnosis would save up to $7.9 trillion in medical and care costs by 2050 in the US alone. However, the emergent pathology is highly variable across people, necehighly variable across people, necessitating individualized diagnostics and interventions. The VirtualBrainCloud addresses this by bridging the gap between computational neuroscience and subcellular systems biology, integrating both research streams into a unifying computational model that supports personalized diagnostics and treatments in NDD. TheVirtualBrainCloud not only integrates existing software tools, it also merges the efforts of two big EU initiatives, namely The Virtual Brain large scale simulation platform of the EU Flagship Human Brain Project and IMI-EPAD initiative (European prevention of Alzheimer’s dementia consortium). VirtualBrainCloud will develop and validate a decision support system that provides access to high quality multi-disciplinary data for clinical practice. The result will be a cloud-based brain simulation platform to support personalized diagnostics and treatments in NDD. The EU PRACE (Partnership for Advanced Computing in Europe) initiative, will provide the required computing infrastructure. The VirtualBrainCloud will develop robust solutions for legal and ethical matters by interacting with EU projects such as European Open Science Cloud (EOSC), ‘cloud4health’, Alzheimer’s Europe patient organizations and ELIXIR, an organization that manages and safeguards EU research data. Our software developers have already produced highly successful brain simulation and clinical decision support tools. The resulting software will be a cloud based computational modeling system that is tailored to the individual, and bridges multiple scales to identify key mechanisms that predict NDD progression and serves as Precision Decision Support System.

Keywords: modelling,simulation,brain,neurodegenerative disease,decision support,big data,cloud,high performance computing
MARA-BASED INDUSTRIAL LOW-COST IDENTIFICATION ASSAYS (MARILIA)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Emerging themes and communities
Action type: Research and Innovation actions
Countries involved: Italy,Italy,Italy,Austria,Croatia
Call: EIC Transition to Innovation Activities (H2020-EIC-FETPROACT-2019, 2019)
Start date: 2020-09-01
End date: 2023-02-28
Duration (months): 30.0
Total project cost (EUR): 2000741.25
EU funding (EUR): 1999972.5
Participants: 6
Project status: CLOSED

The fast and cost-efficient detection of pathogens is highly important in many sectors such as healthcare, agriculture, and food industry. However, current technologies are limited, and significant advances are required to develop low-cost (<10€) detection assays that can detect a few bacterial cells (<10 cells/ml) within less than one hour. In the FET-Open project MARA, which is the basis for MARILIA, we have developed novel technologies and tools that have a high exploitation potential. Thus, we have initiated the follow-up project MARILIA, which aims to exploit these results and realise a new detection concept for the fast, low-cost identification of human pathogens in water samples. In MARILIA, we will increase the technology readiness level (TRL) of our novel detection concept from TRL 2 to TRL 5. A well-balanced consortium has been established, comprising an applied research institute as coordinator (AIT, coordinated also the MARA project), a university (UZ), a basic research institute (RBI), an SME (D1, acting as business incubator) and a large company (IREN, representing a potential future customer). If the MARILIA detection assay meets the requirements defined by IREN, a start-up will be founded to commercially exploit the innovations in the post-project phase.

Keywords: pathogen detection